In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

REGN stock has seen an impact that was slightly ... as evident in HQ Portfolio performance metrics. The views and opinions expressed herein are the views and opinions of the author and do not ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

Ulta Beauty ( ULTA) was the best-performing stock in the S&P 500 after the beauty products retailer beat profit and sales ...

Key Takeaways The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on ...

Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

On Monday, Truist Securities analysts reiterated their Buy rating for Regeneron Pharma (NASDAQ: NASDAQ:REGN) stock, maintaining ... lack of clarity on subgroup performance in the study.

A late-stage trial for a COPD drug developed by Regeneron Pharmaceuticals ... downgraded the stock and lowered its price target on concerns about the firm's future market performance.

We aim to explore its current performance. With a trading volume of 3,313,559, the price of REGN is down by -18.78%, reaching $491.69. Current RSI values indicate that the stock is may be ...

These factors contribute to the immediate cautious outlook for Regeneron’s stock performance. According to InvestingPro ’s Fair Value analysis, the stock appears undervalued at current levels.

My last analysis on REGN noted that the stock is priced for ~3% revenue growth ... Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice ...